TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04198558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0618
Description: MEDI0618 A novel human immunoglobulin antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0618
Description: MEDI0618 A novel human immunoglobulin antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0618
Description: MEDI0618 A novel human immunoglobulin antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0618
Description: MEDI0618 A novel human immunoglobulin antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0618
Description: MEDI0618 A novel human immunoglobulin antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0618
Description: MEDI0618 A novel human immunoglobulin antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0618
Description: MEDI0618 A novel human immunoglobulin antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0618
Description: MEDI0618 A novel human immunoglobulin antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0618
Description: MEDI0618 A novel human immunoglobulin antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT02196844

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hatha Yoga
Description: 5-6 weeks of a couple-based yoga program, three sessions per week (up to 15 sessions) during radiation treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hatha Yoga
Description: 5-6 weeks of a couple-based yoga program, three sessions per week (up to 15 sessions) during radiation treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: 10 questionnaires completed before first radiation treatment, each week during radiation, 5 questionnaires halfway through radiation treatment schedule. at radiation treatment completion, and again 3 months later.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: 10 questionnaires completed before first radiation treatment, each week during radiation, 5 questionnaires halfway through radiation treatment schedule. at radiation treatment completion, and again 3 months later.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: 10 questionnaires completed before first radiation treatment, each week during radiation, 5 questionnaires halfway through radiation treatment schedule. at radiation treatment completion, and again 3 months later.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walk Test
Description: 6-minute walk test performed at baseline, at the end of radiation therapy, and 3 months after radiation therapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walk Test
Description: 6-minute walk test performed at baseline, at the end of radiation therapy, and 3 months after radiation therapy.
Study: NCT02694016

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Description: A blood pressure cuff is placed around the right leg on the level of the thigh. Randomization is performed after this, using sealed envelopes with covariate balancing for age and sex. Regardless of the outcome of the randomization the cuff is left in place so as not to give any indication of which group the patient belongs to. If the patient is randomized into the remote ischemic preconditioning group (RIPC) then four (4) cycles of five (5) minute inflation are given after induction. Each cycle is followed by a five (5) minute interval of reperfusion. Cuff pressure should be 200mgHg at least (RRsyt + 100mmgHg) during the inflation periods.
Study: NCT06367140

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMG-triggered CIMCT device
Description: The study tested an EMG-triggered CIMCT device for stroke rehab, involving EMG sensors, a stationary bike, and a control unit displaying muscle activity. The protocol included warm-up, therapist-guided exercises, and cool-down, performed under supervision.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: general cycling training
Description: The training aimed to improve overall physical fitness and potentially aid in stroke recovery through regular cycling activity, conducted under supervision to ensure participant safety and adherence to the protocol.
Study: NCT02987686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Infliximab
Description: Aside from the standard treatment, patients will receive topical infliximab ( 10mg/ml) four (4) time per day for four (4) weeks.
Study: NCT02717923

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: maintenance treatment with capecitabine plus cetuximab
Description: Using a maintenance treatment strategy of capecitabine plus cetuximab as a treatment option in mCRC after first-line 5-FU-based chemotherapy plus cetuximab
Study: NCT04315740

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Particles from candles
Description: Generating fine and ultrafine particles from lit candles

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Particles from cooking
Description: Generating fine and ultrafine particles from frying pork in an oven

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Clean Air
Description: Nothing but clean air
Study: NCT01807624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracaine HCl 3% and Oxymetazoline HCl 0.05%
Description: 1 spray is 0.2mL is volume and contains 6mg Tetracaine HCl 3% and 0.1mg Oxymetazoline HCl (para-butylaminobenzoic acid or PABA is active metabolite)
Study: NCT01447459

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reinforced Asthma Education
Description: Before beginning the actual study, a board-certified Asthma Educator (AE) will prepare and administer an asthma education training session for the study personnel, including the PI, the co-investigators, and the study coordinator. The AE will also make herself available via pager for assistance with questions from the study personnel regarding asthma education.~At the end of the administration of the phone surveys (i.e. at 2 weeks, 1 month and 3 months following enrollment), the study coordinator will provide reinforced asthma education to the caregiver via telephone for the subjects enrolled in Group A (the intervention group). The reinforced asthma education will be consistent with the asthma education training session delivered by the AE before the beginning of the study.
Study: NCT01443052

Intervention type: OTHER
Intervention: Gait analysis
Description: walking on an electronic walkway GAITRite® at self-selected speed

Intervention type: OTHER
Intervention: Gait analysis
Description: walking on an electronic walkway GAITRite® at self-selected speed

Intervention type: OTHER
Intervention: Gait analysis
Description: walking on an electronic walkway GAITRite® at self-selected speed
Study: NCT00491634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: treosulfan
Description: 12 g/m2 x 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treosulfan
Description: 12 g/m2 x 3
Study: NCT02837770

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac Eye Drops
Description: One drop of Diclofenac 0.1% will be instilled 45' prior to the IVI.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pacebo pill
Description: Pacebo pill will be administered 4 hours before the IVI.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Diclofenac
Description: One Diclofenac Sodium sustained-release 75mg tablet administered per os 4 hours prior to the IVI.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac Eye Drops
Description: One drop of Diclofenac 0.1% will be instilled 45' prior to the IVI.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pacebo pill
Description: Pacebo pill will be administered 4 hours before the IVI.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Artificial Tears
Description: One drop Artificial Tears will be instilled 45' prior to the IVI.
Study: NCT01166282

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: Adalimumab solution for subcutaneous injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: Adalimumab solution for subcutaneous injection.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo for adalimumab
Description: Placebo for adalimumab solution for subcutaneous injection.
Study: NCT04588571

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endovascular recanalization with angioplasty and stenting with the biomimetic interwoven nitinol stent
Description: Under local anesthesia, a standard endovascular approach is performed and the affected arterial segment is visualized. Transluminal or subintimal recanalization of the occluded arterial segment is performed with a hydrophilic guidewire. Next, balloon angioplasty of the recanalized segment is performed. After control angiography, a biomimetic interwoven nitinol stent is placed throughout the lesion.~Drug therapy includes pre-procedure aspirin (160-300 mg/day), starting at least one day before, and intra-procedure heparin (100 U / kg body weight intravenously). After the procedure, all patients have prescribed aspirin (100 mg per day) for a long time and clopidogrel (75 mg per day) for 3 months.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoropopliteal proximal bypass
Description: Under general anesthesia, 2 standard open surgical approaches are performed: first - to the common femoral artery, superficial femoral artery, and deep femoral artery; the second - to the first portion of the popliteal artery. After systemic heparinization, clamps are applied to the arteries. A longitudinal arteriotomy of the popliteal artery is performed, and a distal end-to-side anastomosis is formed between the artery and the shunt. Next, the shunt is passed into the groin wound. Longitudinal arteriotomy of the common femoral artery. A proximal end-to-side anastomosis is formed between the shunt and the common femoral artery. Surgical hemostasis wound drainage and layer-by-layer wound closure are performed.~Drug therapy includes pre-procedure aspirin (160-300 mg/day), starting at least one day before, and intra-procedure heparin (100 U / kg body weight intravenously). After the procedure, all patients have prescribed aspirin (75-100 mg per day) for a long time.
Study: NCT03183297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JMI-001
Description: JMI-001, a combination product of naproxen and fexofenadine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Naproxen sodium 220mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fexofenadine
Description: Fexofenadine 60mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo comparator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo comparator
Study: NCT04109261

Intervention type: DRUG
Intervention: Palbociclib
Description: Palbociclib administration in breast cancer patients included in a compassionate use programme. Patients were treated according to the standard of care
Study: NCT00531661

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HF Pressure Measurement System
Description: A pressure sensor is intended to be implanted into the pulmonary artery at the time of Swan-Ganz catheterization.
Study: NCT00425776

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: acupuncture

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Study: NCT00811018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitaxsentan
Description: Sitaxsentan 100 mg tablets once daily
Study: NCT02640534

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Description: Enzalutamide 160 mg od until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide 160 mg od until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 850 mg bid until disease progression
Study: NCT04347876

Intervention type: DIAGNOSTIC_TEST
Intervention: Tuberculin test
Description: Test the delayed hypersensitivity reaction and immunity to previous BCG vaccination

Intervention type: DIAGNOSTIC_TEST
Intervention: Tuberculin test
Description: Test the delayed hypersensitivity reaction and immunity to previous BCG vaccination
Study: NCT02964143

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cellular Matrix / A-CP HA
Description: Treatment with 2 injections of Cellular Matrix / A-CP HA Kit, administered 2 months apart; Cellular Matrix / A-CP HA Kit is designed for the safe, rapid and extemporaneous preparation of a cellular matrix of autologous PRP combined with HA. The Cellular Matrix / A-CP HA Kit is a single-use medical device including hematology tubes (A-CP HA tube), designed for blood collection and PRP/HA preparation after 5 min centrifugation. This tube contains a non-crosslinked hyaluronic acid (MW 1550 kDa) solution, a gel acting as a cell separator, and a sodium citrate acting as an anticoagulant. During centrifugation, the separator gel moves to form a barrier that separates red blood cells from other blood components. The HA, which migrates to the top of the gradient during centrifugation, can be mixed with PRP in order to give rise to a ready-to-use PRP/HA preparation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ostenil® Plus
Description: Treatment with 2 injections of Ostenil® Plus, administered one week apart; Ostenil® Plus is a solution of sodium hyaluronate obtained by fermentation, containing 0.5% mannitol, a free radical scavenger, which helps to stabilize the chains of sodium hyaluronate. The product is intended to be used for pain and restricted mobility in degenerative and traumatic changes of the knee joint.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RegenKit-BCT-1
Description: Treatment with 2 injections of RegenKit-BCT-1, administered 1 month apart; RegenKit-BCT-1 is designed for the safe, rapid and extemporaneous preparation of autologous platelet-rich plasma. RegenKit-BCT-1 is a single-use medical device including an hematology tube (Regen BCT tube), designed for blood collection and PRP preparation after 5 min centrifugation, and all necessary material for venipuncture and PRP injection. The Regen BCT tube contains a gel acting as a cell separator and a sodium citrate acting as an anticoagulant. During centrifugation, the separator gel moves to form a barrier that separates red blood cells from other blood components.
Study: NCT01170169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole Delayed Release Capsules 40 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prilosec
Description: Prilosec® 40 mg of Merck \& Co.Inc.
Study: NCT00345358

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Synflorix
Description: 1, 2, 3 or 4 Intramuscular injections, depending on age group

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Synflorix
Description: 1, 2, 3 or 4 Intramuscular injections, depending on age group

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Synflorix
Description: 1, 2, 3 or 4 Intramuscular injections, depending on age group

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Synflorix
Description: 1, 2, 3 or 4 Intramuscular injections, depending on age group

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix IPV/Hib
Description: 4 intramuscular injections
Study: NCT04778137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Biological: CMAB007 Biological: Xolair

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omalizumab
Description: Biological: CMAB007 Biological: Xolair
Study: NCT01385293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Description: BKM120 at the maximum tolerated dose (MTD) of 100mg orally daily
Study: NCT06152393

Intervention type: DIAGNOSTIC_TEST
Intervention: Measure of an antibody index for intrathecal synthesis of specific anti-Treponema pallidum IgG by ELISA.
Description: Paired CSF/serum samples from all patients were blind tested for anti-T. pallidum IgG with an ELISA containing recombinant T. pallidum proteins (Euroimmun).~The AI was calculated conforming to Reiber's method (PMID 11239944) and as previously described in Alberto et al. (PMID 35138118).

Intervention type: DIAGNOSTIC_TEST
Intervention: Measure of an antibody index for intrathecal synthesis of specific anti-Treponema pallidum IgG by ELISA.
Description: Paired CSF/serum samples from all patients were blind tested for anti-T. pallidum IgG with an ELISA containing recombinant T. pallidum proteins (Euroimmun).~The AI was calculated conforming to Reiber's method (PMID 11239944) and as previously described in Alberto et al. (PMID 35138118).

Intervention type: DIAGNOSTIC_TEST
Intervention: Measure of an antibody index for intrathecal synthesis of specific anti-Treponema pallidum IgG by ELISA.
Description: Paired CSF/serum samples from all patients were blind tested for anti-T. pallidum IgG with an ELISA containing recombinant T. pallidum proteins (Euroimmun).~The AI was calculated conforming to Reiber's method (PMID 11239944) and as previously described in Alberto et al. (PMID 35138118).
Study: NCT01574729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surgery combined with rAd-p53 gene therapy
Description: Surgery combined with rAd-p53 gene therapy during surgery plus post-surgery chemotherapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Surgery plus post-surgery chemotherapy
Study: NCT01070485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223 chloride (BAY88-8223)
Description: The required volume of study drug to be administered to a patient was calculated using the patient's body weight (50 kBq/kg b.w.).
Study: NCT01877395

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Purified Vero Rabies Vaccine (VRVg)
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Imovax® Rabies: inactivated rabies vaccine
Description: 1.0 mL, Intramuscular
Study: NCT03657082

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEP-10
Description: Bottle PEP with a water level of 10 cmH2O

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEP-10
Description: Bottle PEP with a water level of 10 cmH2O

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEP-1
Description: Bottle PEP with a water level of 1 cmH2O

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEP-1
Description: Bottle PEP with a water level of 1 cmH2O
Study: NCT01012440

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEM Flex Solo II PET Scanner
Description: Subjects will receive bilateral (both sides) breast and axillary PEM scans.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI scan
Description: Subjects will receive bilateral (both sides) breast and axillary MRI scans.
Study: NCT02304367

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Burosumab
Description: Solution for subcutaneous injection
Study: NCT04467372

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tart cherry juice concentrate
Description: Two 8oz bottles of tart cherry juice concentrate daily for 30 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Juice placebo
Description: Two 8oz bottles of placebo juice daily for 30 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Freeze dried tart cherry powder
Description: Two freeze dried tart cherry powder capsules daily for 30 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Capsule placebo
Description: Two placebo capsules daily for 30 days
Study: NCT01525069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Floxuridine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Floxuridine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Floxuridine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Study: NCT01760252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine, Oxaliplatin and Irinotecan (CAPOXIRI)
Description: Neoadjuvant CAPOXIRI chemotherapy is an innovative strategy that builds on the advancement associated with FOLFIRINOX chemotherapy in patients with metastatic disease
Study: NCT04200599

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: duration of initiation of oxytocin
Description: mode of delivery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: duration of initiation of oxytocin
Description: mode of delivery
Study: NCT02784899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iloprost
Description: 20μg(2ml) of inhaled iloprost (Ventavis®)~When anesthesia induction finishes, change patients' position from supine to lateral position and measure arterial blood gas analysis (ABGA), venous blood gas analysis (VBGA) while two lung is ventilated. After 20 minutes of applying one lung ventilation, measure ABGA. Apply iloprost or normal saline inhalation for each iloprost and control group and measure ABGA at the time of 20 min and 40 min after iloprost (or normal saline) inhalation has finished.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: 20μg(2ml) of inhaled normal saline~When anesthesia induction finishes, change patients' position from supine to lateral position and measure ABGA, VBGA while two lung is ventilated. After 20 minutes of applying one lung ventilation, measure ABGA. Apply iloprost or normal saline inhalation for each iloprost and control group and measure ABGA at the time of 20 min and 40 min after iloprost (or normal saline) inhalation has finished.